New Book Shows Billions are Being Wasted on Statins

LONDON - Millions of people already take a statin to lower their cholesterol and
millions more are about to be prescribed these drugs under current
guidelines. However, a new book provides substantial evidence to show that
most people do not need to lower their cholesterol.

‘New Class’ of Coronary Stent Shows Sustained 12-Month Benefit in the Treatment of De Novo Coronary Lesions

NEWNAN, Georgia - The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F offers
sustained benefit in the treatment of de novo coronary lesions and maximizes
endothelialization, while reducing restenosis, thrombogenicity, and the need
for long-term dual-antiplatelet therapy. The CATANIA(TM) Stent may be an
alternative to both BMS and DES. These conclusions, based on 12-month data
from the ATLANTA Trial, were published in the latest issue of the Journal of
the American College of Cardiology: Cardiovascular Interventions.

Ipsogen Announces the CE Marking of its “ProfileQuant(R) WT1″ Kit

MARSEILLE, France - WT1 is a Valuable Biomarker in the Prognosis and Follow-up
of Acute Myeloid Leukemia (AML) Patients.

WBAL Radio Segment With Dr. Leigh Vinocur Addresses Hope for the Rosacea Sufferer

NAPA, California - Dr. Vinocur Reports on University of California Rosacea-Specific Study -

On March 9, 2009, Dr. Leigh Vinocur, medical expert from the University
of Maryland School of Medicine, was featured on WBAL-AM 1090 in a segment on
rosacea, a condition afflicting over 14 million Americans. Dr. Vinocur
addressed current therapies while reporting on a new study conducted at the
Department of Dermatology, University of California, Irvine, in which rosacea
patients were treated with a new cosmeceutical, Pyratine XR(TM) (0.125%
furfuryl tetrahydropyranyl adenine).

ThromboGenics Announces Business Update and 2008 Full Year Results

LEUVEN, Belgium - ThromboGenics Reports Pre-Tax Profit of EUR12.2 Million For 2008

ThromboGenics NV (Euronext Brussels: THR), a biotechnology
company focused on the discovery and development of innovative treatments
that will make a real difference to patient care in a number of important
therapeutic areas, is today issuing a business update and its financial
results for the full year ending December 31, 2008.

BioCis Pharma Starts Phase IIa Trial in Psoriasis

TURKU, Finland - BioCis Pharma Ltd., a privately-held drug development company with its
headquarters in Turku, Finland, announced that it has begun a new Phase IIa
clinical testing of ProtoCure(TM) emulsion cream, the company’s novel topical
drug for dermatology. The double-blind, vehicle-controlled study is designed
to evaluate the tolerability, pharmacokinetics, and efficacy of the topical
product in a total of 18 subjects with mild to moderate plaque psoriasis. The
subjects will apply ProtoCure(TM) emulsion cream up to four weeks to the skin
areas affected by the disease.

European Commission Approves ReFacto AF(TM) as a Variation to the Refacto(R) Marketing Authorisation

MAIDENHEAD, England - Improvements in Purification Process Represent Important Advance in the
Treatment of Haemophilia A

Simbionix Increases Product Offerings for OB/GYN Physicians

CLEVELAND and ZURICH, Switzerland - Simbionix and VirtaMed Have Joined Forces to Provide OB/GYN Surgeons
the Most Advanced Training System for Endoscopic Surgery

TriPollar(TM) POSE(TM) Introduces the Non-Invasive Home-Use Solution to a Sculpted Body

TEL AVIV - New Clinical Device for Body Generates Inch-Loss, Cellulite Reduction
and the Tightening of Lax Skin

Shire Announces Launch of FOSRENOL(R) in Japan

DUBLIN - Availability of Non-Calcium, Non-Resin FOSRENOL(R) Gives New
Therapy Choice for the Management of Hyperphosphataemia in End-Stage Renal
Disease Patients(1) in Japan

Thomson Reuters Publishes Pharma Matters White Paper, ‘The Five Myths of Generic Competition’

PHILADELPHIA and LONDON - Unique Survey Shows Much Room for Originator Pharmaceutical Companies
to Improve Their Understanding of Generic Competition

Further 100 Million Euros Allocated to Netherlands-Based R&D Targeting the Early Diagnosis and Treatment of Disease

EINDHOVEN, The Netherlands - The Center for Translational Molecular Medicine (CTMM) - the Dutch
public-private partnership committed to the research and development of new
techniques for the diagnosis and treatment of major diseases - today
announced that eight new research projects will receive funding from the
CTMM. It means that almost 250 million Euros have now been allocated to
Netherlands-based translational projects that could radically improve patient
outcomes for diseases such as Alzheimer’s, rheumatoid arthritis, sepsis,
cardiovascular disorders and the most important forms of cancer.